Argentina
Australia
Austria
Belgium
Brazil
Canada
Chile
China
Colombia
Costa Rica
Denmark
Ecuador
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
India
Indonesia
Ireland
Italy
Japan
Korea
Latin America
Malaysia
Mexico
Netherlands
Norway
Pakistan
Peru
Philippines
Russia
Singapore
South Africa
Spain
Sweden
Switzerland
Taiwan
Thailand
Turkey
United Kingdom
Venezuela
Vietnam
Lilly
  • Who We Are
    • Lilly for Better
    • Governance
      • Board of Directors
      • Executive Committee
    • Business Areas
      • Bio-Medicines
      • Diabetes
      • Oncology
      • International
      • Elanco Animal Health
    • Key Issues
      • Biosimilars
      • Health Care Reform
      • Intellectual Property
      • Trade
      • U.S. Tax Reform
      • Value-Based Pricing
    • Diversity & Inclusion
      • Diversity in Clinical Trials
      • People and Partnerships
      • Supplier Diversity
    • Lilly Foundation
    • Grant Office
  • Caring
    • Advancing Medical Science
    • Improving Global Health
      • Hunger
      • Patient Programs
    • Strengthening Communities
      • Giving
      • Volunteering
      • Education
    • Operating Responsibly
      • Ethics and Compliance Program
      • Transparency
  • Discovery
    • Clinical Development Pipeline
    • R&D Partnering
    • Clinical Trials
      • Clinical Trials Transparency
      • Expanded Access
    • Research Ethics
  • Products
    • Historic Products
    • HCP Medical Information
    • Patient Safety
      • Patient’s Role
      • Provider’s Role
      • FDA's Role
      • Lilly's Role
    • Anti-Counterfeiting
    • Making Safe, High-Quality Medicine
  • Careers
  • Investors
  • Partners
    • Scientific Areas of Interest
    • Scientific Partnering
  • Newsroom
    • Media Contacts
    • Social Channels
      • Facebook
      • Twitter
      • Instagram
      • LinkedIn
    • Blogs
    • RSS News Feeds
    • Press Releases
      • Press Release Archives
  • Media Contacts
  • Social Channels
  • Blogs
  • RSS News Feeds
  • Press Releases
  • Q3 2017 Earnings Show Strong Performance

    Q3 2017 Earnings Show Strong Performance

  • Lilly Receives FDA Approval of Verzenio™ (abemaciclib)

    FDA Approves Lilly's Verzenio™ (abemaciclib)

  • Humalog® Junior KwikPen® Now Available in the U.S.

    Humalog® Junior KwikPen® Now Available in the U.S. for People with Diabetes

  • Press Release | October 24, 2017

    Lilly Reports Third-Quarter Results, Announces Strategic Review of Elanco Animal Health

    INDIANAPOLIS, Oct. 24, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2017. $ in millions, except per share d…

  • Press Release | October 23, 2017

    Lilly announces $72 million investment in diabetes manufacturing in Indianapolis

    INDIANAPOLIS, Oct. 23, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to invest $72 million in an insulin manufacturing project at one of its Indianapolis facilities. The…

  • Press Release | October 18, 2017

    Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

    INDIANAPOLIS and TÜBINGEN, Germany, Oct. 18, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on the development…

  • LillyPad | October 17, 2017

    The GOP’s Tax Reform Framework is a Step in the Right Direction

    Today’s guest blog comes from Dave Ricks, Lilly CEO. Last month, House Republican leaders unveiled a new plan for bold, comprehensive tax reform to spur growth, create jobs and encourage American comp…

  • LillyPad EU | October 17, 2017

    A Policy Roadmap on Metastatic Breast Cancer

    Click here to download the full report.

Lilly
  • Privacy Statement
  • Terms of Use
  • Diversity
  • Suppliers
  • Login
  • Sitemap
  • Contact

Copyright © 2017 Eli Lilly and Company. All rights reserved.